drugset / Trial / NCT01852513

Allergic Rhinitis Changes the Sinus Microbiome

NCT01852513

Phase 4 Completed 39 enrolled University of Chicago
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The investigators hypothesize that treatment with QNASL will reduce nasal mucosal inflammation induced by the allergy season and prevent the changes in the microbiome caused by the allergy season.

Timeline

Start
2013-01
Primary completion
2013-11
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator beclomethasone dipropionate Other / unclassified 320 ug Intranasal